Osteopontin gene haplotypes correlate with multiple sclerosis development and progression

被引:58
作者
Chiocchetti, A
Comi, C
Indelicato, M
Castelli, L
Mesturini, R
Bensi, T
Mazzarino, MC
Giordano, M
D'Alfonso, S
Momigliano-Richiardi, P
Liguori, M
Zorzon, M
Amoroso, A
Trojano, M
Monaco, F
Leone, M
Magnani, C
Dianzani, U
机构
[1] A Avogadro Univ Eastern Piedmont, Interdisciplinary Res Ctr Autoimmune Dis, I-28100 Novara, Italy
[2] A Avogadro Univ Eastern Piedmont, Dept Med Sci, I-28100 Novara, Italy
[3] Osped Maggiore Novara, Dept Neurol, Novara, Italy
[4] Catania Univ, Dept Biomed Sci, I-95126 Catania, Italy
[5] CNR, Ist Sci Neurol, Cosenza, Italy
[6] Univ Bari, Dept Neurol & Psychiat Sci, Bari, Italy
[7] Univ Trieste, Dept Neurol, Trieste, Italy
[8] Cattinara Hosp, Trieste, Italy
[9] Univ Trieste, Med Genet Unit, Trieste, Italy
[10] IRCCS Burlo Garofolo, Trieste, Italy
关键词
Eta-1; SNP; MS; genetics; progression;
D O I
10.1016/j.jneuroim.2005.02.020
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Osteopontin (OPN) is an inflammatory cytokine highly expressed in multiple sclerosis (MS) plaques. In a previous work, we showed that four OPN polymorphisms form three haplotypes (A, B, and C) and that homozygotes for haplotype-A display lower OPN levels than non-AA subjects. In this work, we evaluated the distribution of these OPN haplotypes in 425 MS patients and 688 controls. Haplotype-A homozygotes had about 1.5 lower risk of developing MS than non-AA subjects. Clinical analysis of 288 patients showed that AA patients displayed slower switching from a relapsing remitting to a secondary progressive form and milder disease with slower evolution of disability. MS patients displayed increased OPN serum levels, which were partly due to the increased frequency of non-AA subjects. Moreover in AA patients, OPN levels were higher than in AA controls and similar to those found in both non-AA patients and controls, which suggests a role of the activated immune response. These data suggest that OPN genotypes may influence MS development and progression due to their influence on OPN levels. (C) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:172 / 178
页数:7
相关论文
共 39 条
  • [1] Eta-1 (osteopontin): An early component of type-1 (cell-mediated) immunity
    Ashkar, S
    Weber, GF
    Panoutsakopoulou, V
    Sanchirico, ME
    Jansson, M
    Zawaideh, S
    Rittling, SR
    Denhardt, DT
    Glimcher, MJ
    Cantor, H
    [J]. SCIENCE, 2000, 287 (5454) : 860 - 864
  • [2] Osteopontin polymorphisms and disease course in multiple sclerosis
    Caillier, S
    Barcellos, LF
    Baranzini, SE
    Swerdlin, A
    Lincoln, RR
    Steinman, L
    Martin, E
    Haines, JL
    Pericak-Vance, M
    Hauser, SL
    Oksenberg, JR
    [J]. GENES AND IMMUNITY, 2003, 4 (04) : 312 - 315
  • [3] THE ROLE OF ETA-1/OSTEOPONTIN IN THE PATHOGENESIS OF IMMUNOLOGICAL DISORDERS
    CANTOR, H
    [J]. OSTEOPONTIN: ROLE IN CELL SIGNALLING AND ADHESION, 1995, 760 : 143 - 150
  • [4] The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease
    Chabas, D
    Baranzini, SE
    Mitchell, D
    Bernard, CCA
    Rittling, SR
    Denhardt, DT
    Sobel, RA
    Lock, C
    Karpuj, M
    Pedotti, R
    Heller, R
    Oksenberg, JR
    Steinman, L
    [J]. SCIENCE, 2001, 294 (5547) : 1731 - 1735
  • [5] High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation
    Chiocchetti, A
    Indelicato, M
    Bensi, T
    Mesturini, R
    Giordano, M
    Sametti, S
    Castelli, L
    Bottarel, F
    Mazzarino, MC
    Garbarini, L
    Giacopelli, F
    Valesini, G
    Santoro, C
    Dianzani, I
    Ramenghi, U
    Dianzani, U
    [J]. BLOOD, 2004, 103 (04) : 1376 - 1382
  • [6] Plasma osteopontin levels in multiple sclerosis
    Comabella, M
    Pericot, I
    Goertsches, R
    Nos, C
    Castillo, M
    Navarro, JB
    Río, J
    Montalban, X
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2005, 158 (1-2) : 231 - 239
  • [7] Defective T cell Fas function in patients with multiple sclerosis
    Comi, C
    Leone, M
    Bonissoni, S
    DeFranco, S
    Bottarel, F
    Mezzatesta, C
    Chiocchetti, A
    Perla, F
    Monaco, F
    Dianzani, U
    [J]. NEUROLOGY, 2000, 55 (07) : 921 - 927
  • [8] The 3′ untranslated region of messenger RNA:: A molecular 'hotspot' for pathology?
    Conne, B
    Stutz, A
    Vassalli, JD
    [J]. NATURE MEDICINE, 2000, 6 (06) : 637 - 641
  • [9] Two single-nucleotide polymorphisms in the 5′ and 3′ ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus
    D'Alfonso, S
    Barizzone, N
    Giordano, M
    Chiocchetti, A
    Magnani, C
    Castelli, L
    Indelicato, M
    Giacopelli, F
    Marchini, M
    Scorza, R
    Danieli, MG
    Cappelli, M
    Migliaresi, S
    Bighardo, B
    Sabbadini, MG
    Baldissera, E
    Galeazzi, A
    Sebastiani, GD
    Minisola, G
    Ravazzolo, R
    Dianzani, U
    Momigliano-Richiardi, P
    [J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (02): : 539 - 547
  • [10] Post-transcriptional gene regulatory mechanisms in eukaryotes: an overview
    Day, DA
    Tuite, MF
    [J]. JOURNAL OF ENDOCRINOLOGY, 1998, 157 (03) : 361 - 371